

IN THE SPOTLIGHT

Issue 84 | May 2021

NEWS & ACHIEVEMENTS



CSI Singapore is proud to announce the promotion of Dr. Polly Chen to Associate Professor!

Congratulations to Dr. Polly Chen on her promotion to Associate Professor!

CSI Singapore is proud to announce the promotion of Dr. Polly Chen to Associate Professor! Dr. Chen joined CSI Singapore in 2014 as a Principal Investigator. Since then, she has received multiple awards in recognition of her outstanding research, including the EMBO Young Investigator Program (YIP) and the Yong Loo Lin School of Medicine Young Researcher Of the Year Award.

[read more >>>](#)



[Listen] Health Matters - New Mechanism that Regulates DNA Connections

Prof. Daniel Tenen shares his team's recent breakthrough on radio station CNA938's "Health Matters with Daniel Martin". In this interview, Prof. Tenen explains how the team has found a new mechanism that regulates DNA connections, which may aid in disease prevention.

[listen now >>>](#)

SAVE THE DATE!



Frontiers in Cancer Science 2021

1 - 3 November 2021
Lee Kong Chian School of Medicine (Novena Campus)

Save the date for the nation's largest annual cancer conference! Stay tuned to our website for updates on FCS 2021.

[read more >>>](#)

Topography of Transcriptionally Active Chromatin in Glioblastoma. (*Sci Adv*, Apr 2021)

In this study on glioblastoma (GBM), Prof. H. Phillip Koeffler and his team unravelled novel insights on the molecular classification, pathogenesis and therapeutic intervention of this deadly brain cancer which is prevalent among adults. Findings from their study revealed core oncogenic dependency on super-enhancer-driven transcriptional factors, long noncoding RNAs, and druggable targets in GBM.



[read more >>>](#)

Targeting RNA Editing of Antizyme Inhibitor 1: a Potential Oligonucleotide-Based Antisense Therapy for Cancer. (*Mol Ther*, May 2021)

While dysregulated adenosine-to-inosine (A-to-I) RNA editing is implicated in various cancers, no available RNA editing inhibitors have been developed so far. A/Prof. Polly Chen's group has taken a step further and investigated the RNA secondary structure of antizyme inhibitor 1 (AZIN1), one of the best-studied A-to-I editing targets in cancer, by locating its editing site complementary sequence (ECS). Results revealed that antisense oligonucleotides (ASOs), which target the ECS, effectively suppresses tumour incidence and growth, underscoring the therapeutic potential of AZIN1-targeting and ASO-based therapeutics.



[read more >>>](#)

Extracellular Vesicles, the Cornerstone of Next-Generation Cancer Diagnosis? (*Semin Cancer Biol*, May 2021)

In this review helmed by Profs Goh Boon Cher and Lee Soo Chin, the group delved into the current techniques of extracellular vesicles (EV) isolation and characterization, and discussed the potential of EV biomarkers catered for specific types of cancer. While they recognize the therapeutic potential of EV biomarkers, the group established that the purification, characterization and biomarker identification process have to be further studied to ensure optimal outcomes for patients.



[read more >>>](#)



Cancer Science Institute of Singapore
National University of Singapore
Centre for Translational Medicine
14 Medical Drive, #12-01
Singapore 117599